{"id":"https://openalex.org/W3012039083","doi":"https://doi.org/10.1200/jop.19.00301","title":"Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib","display_name":"Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib","publication_year":2020,"publication_date":"2020-03-20","ids":{"openalex":"https://openalex.org/W3012039083","doi":"https://doi.org/10.1200/jop.19.00301","mag":"3012039083","pmid":"https://pubmed.ncbi.nlm.nih.gov/32196424"},"language":"en","primary_location":{"id":"doi:10.1200/jop.19.00301","doi":"https://doi.org/10.1200/jop.19.00301","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jop.19.00301","pdf_url":null,"source":{"id":"https://openalex.org/S4210202425","display_name":"JCO Oncology Practice","issn_l":"2688-1527","issn":["2688-1527","2688-1535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-20","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JCO Oncology Practice","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","datacite","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.17615/yrtg-4f72","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047581512","display_name":"Ashley L. Cole","orcid":"https://orcid.org/0000-0001-6765-8868","observed_orcids":["https://orcid.org/0000-0001-6765-8868"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashley L. Cole","raw_affiliation_strings":["Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC","Division of Pharmaceutical Outcomes and Policy, University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill, NC","Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC; Division of Pharmaceutical Outcomes and Policy, University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"Division of Pharmaceutical Outcomes and Policy, University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC; Division of Pharmaceutical Outcomes and Policy, University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016014484","display_name":"William Allen Wood","orcid":"https://orcid.org/0000-0001-7439-2543","observed_orcids":["https://orcid.org/0000-0001-7439-2543"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William A. Wood","raw_affiliation_strings":["UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC","UNC School of Medicine, University of North Carolina, Chapel Hill, NC","UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; UNC School of Medicine, University of North Carolina, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC","institution_ids":["https://openalex.org/I4390039329"]},{"raw_affiliation_string":"UNC School of Medicine, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; UNC School of Medicine, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049167277","display_name":"Benyam Muluneh","orcid":"https://orcid.org/0000-0002-2387-6676","observed_orcids":["https://orcid.org/0000-0002-2387-6676"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benyam Muluneh","raw_affiliation_strings":["Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030530617","display_name":"Jennifer Leigh Lund","orcid":"https://orcid.org/0000-0002-1108-0689","observed_orcids":["https://orcid.org/0000-0002-1108-0689"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer L. Lund","raw_affiliation_strings":["Department of Epidemiology, UNC Gillings School of Public Health, Chapel Hill, NC","UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC","Department of Epidemiology, UNC Gillings School of Public Health, Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Epidemiology, UNC Gillings School of Public Health, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC","institution_ids":["https://openalex.org/I4390039329"]},{"raw_affiliation_string":"Department of Epidemiology, UNC Gillings School of Public Health, Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056882162","display_name":"Jennifer Elston Lafata","orcid":"https://orcid.org/0000-0002-8550-6195","observed_orcids":["https://orcid.org/0000-0002-8550-6195"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Elston Lafata","raw_affiliation_strings":["Division of Pharmaceutical Outcomes and Policy, University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill, NC","UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC","Division of Pharmaceutical Outcomes and Policy, University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmaceutical Outcomes and Policy, University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC","institution_ids":["https://openalex.org/I4390039329"]},{"raw_affiliation_string":"Division of Pharmaceutical Outcomes and Policy, University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041418355","display_name":"Stacie B. Dusetzina","orcid":"https://orcid.org/0000-0002-3907-9196","observed_orcids":["https://orcid.org/0000-0002-3907-9196"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stacie B. Dusetzina","raw_affiliation_strings":["Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN","Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]},{"raw_affiliation_string":"Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.6833,"has_fulltext":true,"cited_by_count":21,"citation_normalized_percentile":{"value":0.91044912,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"16","issue":"5","first_page":"e443","last_page":"e455"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9779999852180481,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9779999852180481,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.006399999838322401,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.005200000014156103,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9409999847412109},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.9810000061988831},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":1.0},{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":1.0},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7509999871253967},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7630000114440918},{"id":"https://openalex.org/keywords/health-care-expenditure","display_name":"health care expenditure","score":0.7979999780654907},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.5860000252723694},{"id":"https://openalex.org/keywords/emergency-department-visits","display_name":"emergency department visits","score":0.9800000190734863},{"id":"https://openalex.org/keywords/second-generation-tkis","display_name":"second-generation TKIs","score":0.8619999885559082},{"id":"https://openalex.org/keywords/real-world-outcomes","display_name":"real-world outcomes","score":0.6539999842643738},{"id":"https://openalex.org/keywords/comparative-effectiveness","display_name":"comparative effectiveness","score":0.5879999995231628},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.5350000262260437},{"id":"https://openalex.org/keywords/medicare-supplemental","display_name":"Medicare Supplemental","score":0.3889999985694885},{"id":"https://openalex.org/keywords/private-insurance","display_name":"private insurance","score":0.6190000176429749},{"id":"https://openalex.org/keywords/propensity-score-weighting","display_name":"propensity score weighting","score":0.44699999690055847},{"id":"https://openalex.org/keywords/subdistribution-hazard-ratio","display_name":"subdistribution hazard ratio","score":0.8709999918937683},{"id":"https://openalex.org/keywords/quantile-regression","display_name":"quantile regression","score":0.7049999833106995}],"concepts":[{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.9730097055435181},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9056814908981323},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.904900074005127},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.6854547262191772},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6185954809188843},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.4947180449962616},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.4819938540458679},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.4533393681049347},{"id":"https://openalex.org/C88879693","wikidata":"https://www.wikidata.org/wiki/Q217690","display_name":"Cumulative incidence","level":3,"score":0.4231418967247009},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3466285467147827},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.18559765815734863},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.14220315217971802}],"mesh":[{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000069439","descriptor_name":"Dasatinib","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005102","descriptor_name":"Health Expenditures","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006278","descriptor_name":"Medicare","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1200/jop.19.00301","doi":"https://doi.org/10.1200/jop.19.00301","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jop.19.00301","pdf_url":null,"source":{"id":"https://openalex.org/S4210202425","display_name":"JCO Oncology Practice","issn_l":"2688-1527","issn":["2688-1527","2688-1535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-20","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JCO Oncology Practice","raw_type":"journal-article"},{"id":"pmid:32196424","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32196424","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JCO oncology practice","raw_type":"Journal Article"},{"id":"pmh:cdr.lib.unc.edu:d504rx205","doi":null,"is_oa":true,"landing_page_url":"https://cdr.lib.unc.edu/downloads/cf95jp454","pdf_url":"https://doi.org/10.17615/yrtg-4f72","source":{"id":"https://openalex.org/S4306401075","display_name":"Carolina Digital Repository (University of North Carolina at Chapel Hill)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I114027177","host_organization_name":"University of North Carolina at Chapel Hill","host_organization_lineage":["https://openalex.org/I114027177"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"JCO Oncology Practice, 16(5)","raw_type":"Article"},{"id":"doi:10.17615/yrtg-4f72","doi":"https://doi.org/10.17615/yrtg-4f72","is_oa":true,"landing_page_url":"https://doi.org/10.17615/yrtg-4f72","pdf_url":null,"source":{"id":"https://openalex.org/S7407051488","display_name":"UNC Libraries","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"}],"best_oa_location":{"id":"pmh:cdr.lib.unc.edu:d504rx205","doi":null,"is_oa":true,"landing_page_url":"https://cdr.lib.unc.edu/downloads/cf95jp454","pdf_url":"https://doi.org/10.17615/yrtg-4f72","source":{"id":"https://openalex.org/S4306401075","display_name":"Carolina Digital Repository (University of North Carolina at Chapel Hill)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I114027177","host_organization_name":"University of North Carolina at Chapel Hill","host_organization_lineage":["https://openalex.org/I114027177"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"JCO Oncology Practice, 16(5)","raw_type":"Article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[{"id":"https://openalex.org/G2696436381","display_name":"UNC-CH TRAINING PROGRAM IN HEALTH SERVICES RESEARCH","funder_award_id":"T32HS000032","funder_id":"https://openalex.org/F4320332177","funder_display_name":"Agency for Healthcare Research and Quality"}],"funders":[{"id":"https://openalex.org/F4320332177","display_name":"Agency for Healthcare Research and Quality","ror":"https://ror.org/03jmfdf59"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3012039083.pdf","grobid_xml":"https://content.openalex.org/works/W3012039083.grobid-xml"},"referenced_works_count":43,"referenced_works":["https://openalex.org/W1944742142","https://openalex.org/W1966921577","https://openalex.org/W1968747503","https://openalex.org/W1977996924","https://openalex.org/W1990419463","https://openalex.org/W1993678255","https://openalex.org/W2010901133","https://openalex.org/W2038981426","https://openalex.org/W2051566553","https://openalex.org/W2068248632","https://openalex.org/W2070507117","https://openalex.org/W2097799776","https://openalex.org/W2110818436","https://openalex.org/W2112942078","https://openalex.org/W2125194720","https://openalex.org/W2140201096","https://openalex.org/W2140259730","https://openalex.org/W2146658081","https://openalex.org/W2149797825","https://openalex.org/W2150291618","https://openalex.org/W2157358083","https://openalex.org/W2160811827","https://openalex.org/W2168833663","https://openalex.org/W2193292762","https://openalex.org/W2212259343","https://openalex.org/W2220816567","https://openalex.org/W2245246676","https://openalex.org/W2258178934","https://openalex.org/W2264767503","https://openalex.org/W2273596475","https://openalex.org/W2318149894","https://openalex.org/W2329556022","https://openalex.org/W2343511371","https://openalex.org/W2428296383","https://openalex.org/W2473480037","https://openalex.org/W2521911861","https://openalex.org/W2528188718","https://openalex.org/W2590307110","https://openalex.org/W2600212366","https://openalex.org/W2791438625","https://openalex.org/W2793387867","https://openalex.org/W2802371729","https://openalex.org/W2802556859"],"related_works":["https://openalex.org/W6925201272","https://openalex.org/W3003727246","https://openalex.org/W2564377031","https://openalex.org/W4417006563","https://openalex.org/W4413777130","https://openalex.org/W3048361238","https://openalex.org/W2178307115","https://openalex.org/W2763919110","https://openalex.org/W2189196502","https://openalex.org/W2234278652"],"abstract_inverted_index":{"PURPOSE:":[0],"Tyrosine":[1],"kinase":[2],"inhibitors":[3],"(TKIs)":[4],"have":[5],"dramatically":[6],"improved":[7],"survival":[8,18],"for":[9,67,316],"patients":[10,23,54,61,144,175,214,251],"with":[11,55,171,195,256],"chronic":[12],"myeloid":[13],"leukemia":[14],"(CML).":[15],"No":[16],"overall":[17,307],"differences":[19,305],"were":[20,116,137,242,247],"observed":[21],"between":[22,47,80],"initiating":[24,252],"first-":[25],"and":[26,34,43,51,76,84,101,127,152,168,185,224,246,295],"second-generation":[27,253],"TKIs":[28,254],"in":[29,72,105,261,306],"trials;":[30],"however,":[31],"real-world":[32],"safety":[33,42,160,209],"cost":[35],"outcomes":[36],"are":[37],"unclear.":[38],"We":[39],"evaluated":[40],"comparative":[41],"health":[44,134,239,297],"care":[45,135,240,298],"expenditures":[46,136,241],"first-line":[48,314],"imatinib,":[49,68,148,164,265,274],"dasatinib,":[50,69,151,166],"nilotinib":[52,71,186,225,272],"among":[53,174,213,234,250],"CML.":[56],"PATIENTS":[57],"AND":[58],"METHODS:":[59],"Eligible":[60,143],"had":[62,285],"one":[63],"or":[64,70,110,291],"more":[65],"fills":[66],"the":[73,91,106,205,286,312],"MarketScan":[74],"Commercial":[75],"Medicare":[77],"Supplemental":[78],"databases":[79],"January":[81],"1,":[82],"2011,":[83],"December":[85],"31,":[86],"2016":[87],"(earliest":[88],"fill":[89],"is":[90],"index":[92],"date),":[93],"6":[94],"months":[95],"pre-index":[96,107],"continuous":[97],"enrollment,":[98],"CML":[99],"diagnosis,":[100],"no":[102],"TKI":[103],"use":[104],"period.":[108],"Hospitalizations":[109],"emergency":[111,292],"department":[112,293],"visits":[113,294],"(safety":[114],"events)":[115],"compared":[117,138,194,255],"across":[118],"treatment":[119],"groups":[120],"using":[121,139],"propensity-score-weighted":[122],"1-year":[123,157,296],"relative":[124],"risks":[125,173],"(RRs)":[126],"subdistribution":[128],"hazard":[129],"ratios":[130],"(HRs).":[131],"Inflation-adjusted":[132],"annual":[133],"quantile":[140],"regression.":[141],"RESULTS:":[142],"included":[145],"1,417":[146],"receiving":[147,150,154,176,197,215,236,258,283],"1,067":[149],"647":[153],"nilotinib.":[155],"The":[156],"risk":[158,288],"of":[159,202,208,289,303],"events":[161,210],"was":[162,211],"high:":[163],"37%;":[165],"44%;":[167],"nilotinib,":[169],"40%,":[170],"higher":[172,212,249],"dasatinib":[177,216,263],"(RR,":[178,187],"1.17;":[179],"95%":[180,189,219,228,267,276],"CI,":[181,190,220,229,268,277],"1.06":[182],"to":[183,192,222,231,270,279],"1.30)":[184],"1.07;":[188],"0.93":[191],"1.23)":[193],"those":[196,235,257],"imatinib.":[198,237],"Over":[199],"a":[200,301],"median":[201],"1.7":[203],"years,":[204],"cumulative":[206],"incidence":[207],"(HR,":[217,226],"1.23;":[218],"1.10":[221],"1.38)":[223],"1.08;":[227],"0.95":[230],"1.24)":[232],"than":[233],"One-year":[238],"high":[243],"(median,":[244],"$125,987)":[245],"significantly":[248],"imatinib":[259,284,309],"(difference":[260],"medians:":[262],"v":[264,273],"$22,393;":[266],"$17,068":[269],"$27,718;":[271],"$19,463;":[275],"$14,689":[278],"$24,236).":[280],"CONCLUSION:":[281],"Patients":[282],"lowest":[287],"hospitalization":[290],"expenditures.":[299],"Given":[300],"lack":[302],"significant":[304],"survival,":[308],"may":[310],"represent":[311],"ideal":[313],"therapy":[315],"patients,":[317],"on":[318],"average.":[319]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":6}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-03-23T00:00:00"}